Shuichi Kaneko

Kanazawa University — Japan

Medicine · Health Sciences

51h-index10.9kcitations372works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(51), Hepatitis C virus research(45), Axon Guidance and Neuronal Signaling(43), Hepatitis B Virus Studies(30), Biomarkers in Disease Mechanisms(17)

Publications369 total

The <i>SELENOP</i> Polymorphism rs7579 Predicts Hepatic Steatosis in Females With Insulin Resistance in the General Population
Journal of the Endocrine Society·2025Open Access
Wnt/Beta-Catenin Signaling Regulates Hepatitis B Virus cccDNA Levels
Preprints.org·2025Open Access
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma
ESMO Open·2025· 4 citedOpen Access
Maintenance of R-loop structures by phosphorylated hTERT preserves genome integrity
Nature Cell Biology·2024· 6 cited
Serum <scp>MYCN</scp> as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence
International Journal of Cancer·2024· 6 citedOpen Access
Mint3-depletion-induced energy stress sensitizes triple-negative breast cancer to chemotherapy via HSF1 inactivation
Cell Death and Disease·2023· 21 citedOpen Access
TABLE 1B from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
FIGURE 6 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
FIGURE 1 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
Supplementary Table S9 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
FIGURE 4 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
Supplementary Table S5 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
Supplementary Table S8 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
Supplementary Table S6 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
TABLE 2 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
FIGURE 3 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
Supplementary Fig. S5 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
Supplementary Table S3 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
TABLE 1A from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
Supplementary Table S7 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
2023Open Access
page 1 of 19Next →

Frequent Co-authors

Masao Honda(25), Taro Yamashita(16), Yoshio Sakai(11), Eishiro Mizukoshi(10), Toshinari Takamura(9), Tatsuya Yamashita(9), Hirofumi Misu(7), Tsuguhito Ota(7), Akito Sakai(6), Takayoshi Shirasaki(6), Seishi Murakami(5), Seiichiro Kurita(5), Yumie Takeshita(5), Hikari Okada(5), Kuniaki Arai(5), Kenkichi Masutomi(4), Hiroaki Takayama(4), Naoto Nagata(4), Hitoshi Ando(4), Yasuni Nakanuma(4)